Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desmopressin ODT for Nocturia in Japanese Women
NCT02905682Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Sep 2016
- Primary completion
- Sep 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of desmopressin in nocturia, sponsored by Ferring Pharmaceuticals. Primary endpoint: Change from baseline in mean number of nocturnal voids at 12 weeks. Started Sep 2016; status: completed.
02
Drugs
desmopressin
03
Conditions
nocturia
Beyond the preview
Go deeper on NCT02905682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905682.